This is a preview of subscription content, access via your institution.
Literatur
Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36:276–282. https://doi.org/10.1200/JCO.2017.75.5009
Saborowski A, Lehmann U, Vogel A (2020) FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? Ther Adv Med Oncol 12:1758835920953293
Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2021) Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 7:1669–1677
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
P.S. Plum, I. Gockel, A. Hillmer und H. Alakus geben an, dass kein Interessenkonflikt besteht.
Additional information

QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Plum, P.S., Gockel, I., Hillmer, A. et al. Irreversible Blockade von FGFR2-positiven intrahepatischen Cholangiokarzinomen – die FOENIX-CCA2-Studie kommentiert. Onkologie 29, 366–367 (2023). https://doi.org/10.1007/s00761-023-01335-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-023-01335-8